Blinatumomab therapy for B cell acute lymphoblastic leukemia accompanied by persistent or relapsed low-level MRD prior to hematopoietic stem cell transplantation in Chinese children: a case series

Bulletin of the National Research Centre

Table 1 Clinical features of the three cases

Case	Age	Sex	Disease status	Cytogenetics	Pre-MRD %MNC	Post-MRD %MNC	Fever	Grade 3/4 toxicities	Days to HSCT*	Graft source	Post-HSCT days
1	5Y7M	M	CR1	46, XY	0.03	< 0.01	Yes	None	21	Haplo sib, PBSC + UCB	54
2	1Y1M	F	CR1	KMT2A-AFF1; t (4;11) (q21;q23)	0.72	< 0.01	Yes	None	22	Haplo sib, PBSC + BM + UCB	80
3	5Y1M	F	CR1	ETV6-RUNX1	0.12	< 0.01	Yes	None	19	Haplo sib, PBSC + UCB	124

Y year, M month, BM bone marrow, MNC mononuclear cell, PBSC peripheral blood stem cell, UCB umbilical cord blood, UCB umbilical cord blood
^*Days to HSCT represents the time from the end of blinatumomab treatment to the day of stem cell infusion
^*Post-HSCT days represents the time from the day of stem cell infusion to May 15, 2022